135,722 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 135,722 shares of the biotechnology company's stock, valued at approximately $208,000. Raymond James Financial Inc. owned about 0.09% of Heron Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Congress Park Capital LLC increased its holdings in Heron Therapeutics by 24.1% in the 4th quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company's stock worth $3,757,000 after buying an additional 477,417 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Heron Therapeutics by 449.0% in the third quarter. XTX Topco Ltd now owns 297,568 shares of the biotechnology company's stock worth $592,000 after acquiring an additional 243,363 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Heron Therapeutics by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after purchasing an additional 154,487 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Heron Therapeutics by 50.4% in the third quarter. BNP Paribas Financial Markets now owns 275,946 shares of the biotechnology company's stock worth $549,000 after purchasing an additional 92,425 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Heron Therapeutics by 26.2% during the 3rd quarter. FMR LLC now owns 431,906 shares of the biotechnology company's stock valued at $859,000 after buying an additional 89,601 shares during the period. 80.01% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

A number of analysts recently commented on the company. StockNews.com cut Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Needham & Company LLC reaffirmed a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday.

Heron Therapeutics Price Performance

Shares of HRTX stock traded down $0.01 on Tuesday, hitting $1.92. 696,140 shares of the stock traded hands, compared to its average volume of 2,365,130. The firm has a market cap of $292.47 million, a price-to-earnings ratio of -10.67 and a beta of 1.39. The firm has a 50 day simple moving average of $2.06 and a two-hundred day simple moving average of $1.78. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.05. The business had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. Sell-side analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.